Advertisement

Topics

Ixekizumab (Taltz) - Biotech, Pharma and Life Science Channel

23:19 EDT 24th May 2017 | BioPortfolio

Ixekizumab (Taltz) is a humanised IgG4 monoclonal antibody that selectively binds with high affinity to the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.iii IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses, and elevated levels of IL-17A have been implicated in the pathogenesis of a variety of autoimmune diseases such as psoriasis.iii  Neutralisation of IL-17A by ixekizumab inhibits these pro-inflammatory actions.iii

Ixekizumab is administered by subcutaneous injection, either via auto-injector or prefilled syringe.iii

In UNCOVER-1 the results show that when treated every two weeks with ixekizumab for 12 weeks following a starting dose, approximately 9 of 10 patients achieved a PASI 75 score.iiiIn both UNCOVER-2 and UNCOVER-3 etanercept was used as an active comparator. The results show that approximately 9 of 10 patients treated with ixekizumab every two weeks achieved a PASI 75 score at week 12, and approximately 8 of 10 patients achieved clear or almost clear skin as defined by sPGA 0 or 1 respectively.iii,

Numerous secondary end points were also collected from the UNCOVER series of trials, including higher levels of clearance, (PASI 90, 100 and sPGA 0). The impact of psoriasis on patient's lives was assessed using patient reported outcome measures, including the DLQI. Across UNCOVER-1 and UNCOVER 2&3, 35.3 percent and 39 percent of patients, respectively achieved PASI 100 (clear skin) after 12 weeks of treatment with ixekizumab.iii

The approved dosing regimen for ixekizumab is a 160-mg starting dose by subcutaneous injection (two 80-mg injections) at Week 0, followed by 80 mg (one injection) every two weeks through 12 weeks, then maintenance dosing of 80 mg (one injection) every four weeks.iii

Lilly received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on February 25, 2016.v

Safety information

The very common (≥1/10 patients) adverse events in clinical trials were injection site reactions and upper respiratory tract infections (most frequently nasopharyngitis).iii

About the UNCOVER Studies

The UNCOVER-1, UNCOVER-2 and UNCOVER-3 studies are double-blind, multicentre, Phase III studies evaluating more than 3,800 patients with moderate-to-severe plaque psoriasis from 21 countries.iii

All three studies evaluated the safety and efficacy of different dosing regimens of ixekizumab (80 mg every two or four weeks, following a 160-mg starting dose) compared to placebo after 12 weeks.iii

·       UNCOVER-2 and UNCOVER-3 included an additional comparator arm in which patients received etanercept (50 mg twice a week) for 12 weeks.iv

·       UNCOVER-1, UNCOVER-2 and UNCOVER-3 also evaluated response rates with ixekizumab during the maintenance period through 60 weeks, with UNCOVER-1 and UNCOVER-2 employing a randomized withdrawal design.iii,iv

·       In these studies, the co-primary efficacy endpoints at 12 weeks were Psoriasis Area Severity Index (PASI) 75 and static Physician’s Global Assessment (sPGA) 0 or 1.iiiPASI measures the extent and severity of psoriasis by assessing average redness, thickness and scaliness of skin lesions (each graded on a zero to four scale), weighted by the body surface area of involved skin, while the sPGA is the physician’s assessment of severity of a patient’s psoriasis lesions overall at a specific point in time.vi Both assessment tools (PASI and sPGA) are in line with CHMP guidelines to assess the effectiveness of treatments for psoriasis.vii

 

News Articles [126 Associated News Articles listed on BioPortfolio]

Psoriatic Arthritis Pipeline Review, H1 2017 [Updated: 23052017] Prices from USD $2000

Psoriatic Arthritis Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis Pipeline Review, H1 2017, provides an overv...

Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab

MUMBAI, India and PRINCETON, N.J., May 24, 2017 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its ...

Phototherapy Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

LONDON, May 23, 2017 /PRNewswire/ -- Global Phototherapy Equipment Market: OverviewThe report on the phototherapy equipment market analyzes the current and future scenario of the global market. Increa...

Net Promotor Score NPS+ EU5 [PsO] [Updated: 01042017] Prices from USD $2575

Biosimilars take the biggest hit as doctors voice dissatisfaction with psoriasis treatmentsDermatologists say they're satisfied with available psoriasis treatments. So why did only 3 of the brands we ...

Net Promotor Score NPS+ US [PsO] [Updated: 01042017] Prices from USD $2575

Two psoriasis treatments get a thumbsdown from otherwise satisfied doctorsDermatologists may be happy with psoriasis treatments overall, but they gave dismal satisfaction scores to 2 of the 8 brands w...

Market Access Impact EU5 [PsO] [Updated: 01032017] Prices from USD $5145

Eliminating market barriers could lift the last place brand into the middle of the packIn the EU5 countries, market barriers affect nearly a quarter of psoriasis prescriptions. Most of the brands we s...

Market Access Impact US [PsO] [Updated: 01032017] Prices from USD $5145

Top brand takes a big lead thanks to market barriersIn the US, market barriers are having a major impact on the brands used to treat psoriasisaffecting more than a third of all prescriptions and helpi...

Medical Affairs Reputations EU5 [PsO] [Updated: 01022017] Prices from USD $6175

Compare 10 psoriasis medical affairs teams. See how your team stacks up to the market leader In the EU5, several of the psoriasis medical affairs teams we surveyed are running neck and neck with at le...

Medical Affairs Reputations US [PsO] [Updated: 01022017] Prices from USD $6175

Close rivalries among US psoriasis medical affairs teams. Will your team come out on top? In the US, nearly all of the psoriasis medical affairs teams we surveyed are running neck and neck with at lea...

Psoriasis KOL Insight [Updated: 01072016] Prices from USD $7900

Will innovative drugs or biosimilars dominate in psoriasis?The emergence of biosimilar antiTNFs could expand access to established biological therapies for psoriasis. However, recently launched therap...

Events [0 Results]

None

Companies [20 Associated Companies listed on BioPortfolio]

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...

Helmedix Pty Ltd

Helmedix is developing new therapies for autoimmune diseases. The company has identified peptides derived from helminthic worms that have immune-modulating properties. These peptides are being explo...

HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of...

fOCUS Pharmaceuticals, LLC

fOCUS Pharmaceuticals is a privately held generic and branded pharmaceutical company specializing in the research and development of prescription dermatology products. Our primary focus are in the are...

Lycera Corp.

Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, i...

Clinical Trials [538 Associated Clinical Trials listed on BioPortfolio]

A Study of KY1005 in Healthy Volunteers and Volunteers With Psoriasis

This is a single and multiple ascending dose, placebo-controlled, double-blind, Phase 1 study to evaluate the safety and tolerability of KY1005 in healthy volunteers and volunteers with mi...

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying...

Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients

To identify possible genetic associations of clinical response to anti-IL-17A (Secukinumab) treatment in psoriasis using a combined gene association study and gene expression analysis. To...

Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients

This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast. This data will be complemented by immunohistochemical...

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

This is a study to assess the pharmacokinetics, safety and tolerability of multiple ascending oral doses of ABBV-553 in healthy volunteers and the pharmacokinetics, safety, tolerability an...

The DIET Trial - Dietetic Intervention in Psoriatic Arthritis

Psoriasis (Ps) and psoriatic arthritis (PsA) are associated with increased risk of metabolic syndrome (MetS), body fatness and cardiovascular risk. Additionally, oxidative stress and infla...

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.

Safety and Efficacy of Secukinumab in Mild Psoriasis

Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mil...

Regulation of Inflammatory Genes in Psoriasis

Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells ...

PubMed Articles [355 Associated PubMed Articles listed on BioPortfolio]

Biomarkers for psoriasis skin lesions.

Psoriasis is a common, chronic skin disease, whose diagnosis is based mainly on clinical features but, in some cases, can be difficult. As the exact diagnosis of psoriasis and the differential diagnos...

The management of moderate-to-severe chronic plaque psoriasis.

Recent approval and marketization of novel treatments have widened the range of therapeutic opportunities for moderate-to-severe psoriasis. In the next years, this panorama will be further enlarged as...

Management of psoriatic arthritis (PsA) among cutaneous psoriasis: from pathogenesis to therapy.

Psoriatic arthritis (PsA) is an inflammatory rheumatism belonging to spondylarthritis family and which occurs in about 30% of patients with psoriasis. The pathogenesis entails a genetic predisposition...

Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.

The aim of this study was to assess the psychometric properties of the five-level (EQ-5D-5L) in comparison with the standard three-level (EQ-5D-3L) classification systems of the EQ-5D in a sample of p...

Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis.

We used a southern Swedish cohort of psoriasis (PSO) and psoriatic arthritis (PsA) patients and population-based referents (N = 57,800) to investigate the influence of socioeconomic and demographic ...

Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey.

Psoriasis patients demonstrate high interest in the role of diet on their skin condition. However, data are lacking to describe dietary interventions among psoriasis patients and associated outcomes. ...

Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review.

To systematically review the role of musculoskeletal US in patients suffering from PsA or psoriasis (Pso) in terms of prevalence, diagnosis, prognosis, monitoring and treatment.

Pediatric Psoriasis Comorbidity Screening Guidelines.

Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis...

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.

The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, ...

A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.

Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hi...

Videos

None available.

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Quick Search
Advertisement
 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

review and buy Ixekizumab (Taltz) market research data and corporate reports here

Channels Quicklinks